Quotables
"We are probably nearing the limit of all we can know about astronomy."
Simon Newcomb, astronomer ; 1888
PatentStorm News
Make the Most of Our Site
See this month's Top Inventors and Most Cited Patents.
Stay on top of the latest innovations by subscribing to an RSS feed.
Registered users: Manage your profile.
| Number | Title | Issue Date |
| 7462607 | Therapy-enhancing glucan This invention provides a composition comprising an effective amount of (1-3),(1-4)-β-glucan derived from barley capable of enhancing efficacy of antibodies. This invention further provides the above compositions and a pharmaceutically acceptable carrier. This inve... | 12/09/2008 |
| 7446190 | Nucleic acids encoding chimeric T cell receptors Chimeric T cell receptors (TCR) are provided that combine, in a single chimeric species, the intracellular domain of CD3 ζ-chain, a signaling region from a costimulatory protein such as CD28, and a binding element that specifically interacts with a selected target.... | 11/04/2008 |
| 7439359 | Small molecule compositions for binding to hsp90 Structural differences in binding pockets of members of the HSP90 family can be exploited to achieve differential degradation of kinases and other signaling proteins through the use of designed small molecules which interact with the N-terminal binding pocket with a... | 10/21/2008 |
| 7384964 | Synthesis of epothilones, intermediates thereto, analogues and uses thereof The present invention provides compounds of formula (I): as described generally and in classes and subclasses herein. The present invention additionally provides pharmaceutical compositions comprising compounds of formula (... | 06/10/2008 |
| 7345174 | Cytodifferentiating agents and histone deacetylase inhibitors, and methods of use thereof The present invention provides the compound having the formula: wherein each of R1 and R2 is, substituted or unsubstituted, aryl, cycloalkyl, cycloalkylamino, naphtha, pyridineamino, piperidino, t-buty... | 03/18/2008 |
| 7271160 | Methods and compositions for degradation and/or inhibition of HER-family tyrosine kinases Bifunctional molecules comprising two hsp-binding moieties which bind to hsp90 in the pocket to which ansamycin antibiotics bind connected via a linker are effective for inducing the degradation and/or inhibition of HER-family tyrosine kinases. For example, a... | 09/18/2007 |
| 7267951 | Method for evaluating a tissue or biopsy sample to determine if the sample is early-stage melanoma A tissue or biopsy sample is evaluated to determine if the sample is early-stage melanoma by determining the level of inhibitor of DNA-binding protein 1 (Id1) expression in cells of the sample; and comparing the determined amount of Id1 to a reference level. The pre... | 09/11/2007 |
| 7247719 | Primers and probes for amplification and detection of human inhibitor of DNA-binding Oligonucleotide primers and polynucleotide probes provide selective amplification and detection of Id genetic sequences and are selected both (1) to provide the desired specificity so that they amplify only the specific Id type to which they are targeted; and (2) to... | 07/24/2007 |
| 7244604 | HDAC9 polypeptides and polynucleotides and uses thereof The present invention features substantially pure HDAC9, HDAC9a, HDAC9(ΔNLS), HDAC9a(ΔNLS), an HDRP(ΔNLS) polypeptides, and isolated nucleic acid molecules encoding those polypeptides. The present invention also features vectors containing HDAC9, HDAC9a, HDAC9(Δ... | 07/17/2007 |
| 7238682 | Methods and compositions for degradation and/or inhibition of HER-family tyrosine kinases Bifunctional molecules comprising two hsp-binding moieties which bind to hsp90 in the pocket to which ansamycin antibiotics bind connected via a linker are effective for inducing the degradation and/or inhibition of HER-family tyrosine kinases. For example, a compou... | 07/03/2007 |
| 7211562 | Methods for enhancing the efficacy of cytotoxic agents through the use of HSP90 inhibitors The administration of cytotoxic agents followed by the administration of heat shock protein 90 inhibitors, such as ansamycins, has a synergistic effect on the growth inhibition of cells. This synergy occurs at doses of each cytotoxic agent that normally only causes ... | 05/01/2007 |
| 7205142 | Nucleic acid sequence encoding ovarian antigen, CA125, and uses thereof The present invention provides an isolated nucleic acid molecule comprising sequences encoding the CA125 protein or a portion thereof. This invention also provides a method to detect ovarian cancer in a subject. Furthermore, this invention provides a method for the ... | 04/17/2007 |
| 7199134 | Hydroxamic acid compounds and methods of use thereof The present invention relates to a novel class of hydroxamic acid derivatives having at least two aryl containing groups, at least one of which is a quinolinyl, isoquinolinyl or benzyl moiety, linked to the hydroxamic acid group through a methylene chain. The hydrox... | 04/03/2007 |
| RE38506 | Potent inducers of terminal differentiation and methods of use thereof The present invention provides the compound having the structure: wherein each of R1 and R2 are independently the same as or different from each other; when R1 and R2 are the same, each i... | 04/20/2004 |
| 4908434 | Process for preparing purified interleukin-2 Interleukin 2 (IL 2; T-cell growth factor), produced with and without costimulation by Burkitt's lymphoma line Daudi, is highly purified approximately over 37,000-fold to apparent homogeneity from lymphocyte-conditioned medium derived from normal huma Thi... | 03/13/1990 |
